不确定潜能的克隆性造血与冠心病患者死亡率
该研究对8612例经血管造影确诊的冠心病患者进行13个CHIP驱动基因的靶向深度测序,将变异等位基因频率≥2%的CHIP携带者与未携带者按1:1倾向性评分匹配,评估3年死亡率。结果显示CHIP与3年死亡率增加相关(HR 1.39,95%CI 1.16-1.65,P<.001),TET2突变通过上调LDLR和炎症激活促进促动脉粥样硬化巨噬细胞表型。
要点
- CHIP是冠心病患者死亡率的预测因素,3年死亡风险增加39%。
- TET2等8个基因突变各自独立增加死亡风险。
- TET2突变通过LDLR上调与炎症激活促动脉粥样硬化。
核心结论
- CHIP是冠心病患者死亡率的预测因素。
- TET2突变通过LDLR上调和炎症激活促进促动脉粥样硬化巨噬细胞表型,将表观遗传失调与CAD不良结局联系起来。
研究设计与样本
- 对8612例经血管造影确诊的冠心病患者进行13个CHIP驱动基因的靶向深度测序。
- 将变异等位基因频率≥2%的CHIP携带者与未携带者按1:1倾向性评分匹配,评估3年死亡率。
- 机制研究来自尸体高灵敏度斑块蛋白质组学(MISSION)、颈动脉斑块RNA测序(Athero-Express)、单核细胞来源巨噬细胞转录组(STARNET)及CRISPR/Cas9生成的TET2+/-巨噬细胞体外实验。
主要发现
- 在2389对匹配患者中,CHIP与3年死亡率增加相关(HR 1.39,95%CI 1.16-1.65,P<.001)。
- TET2、ASXL1、DNMT3A、JAK2、PPM1D、SF3B1、SRSF2和U2AF1突变各自独立增加死亡风险。
- 人斑块中病变巨噬细胞携带CHIP突变;TET2 CHIP携带者坏死核心增大、炎症增加、斑块稳定性降低。
- 多组学分析显示脂质代谢和炎症通路上调;TET2+/-巨噬细胞LDLR表达和脂质摄取增加,与LDLR启动子染色质可及性增强相关。
- 颈动脉斑块中TET2 CHIP携带者LDLR和炎症小体相关基因表达增加。
临床怎么用
- CHIP检测可能有助于冠心病患者风险分层。
- TET2突变携带者可能从针对LDLR通路或炎症的干预中获益,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Clonal haematopoiesis of indeterminate potential (CHIP) has been associated with cardiovascular risk, but its prognostic relevance and mechanistic role in coronary artery disease (CAD) remains incompletely understood. This study investigated the association between CHIP and all-cause mortality in CAD and explored the cellular and molecular mechanisms, focusing on TET2 mutations. METHODS: Targeted deep sequencing of 13 CHIP driver genes in 8612 patients with angiographically confirmed CAD was performed. Clonal haematopoiesis of indeterminate potential carriers (variant allele frequency ≥2%) were propensity-score matched 1:1 to non-carriers. Mortality was assessed over 3 years. Mechanistic insights were derived from post-mortem high-sensitivity plaque proteomics (MISSION), RNA sequencing from carotid plaques (Athero-Express), monocyte-derived macrophage transcriptomes (STARNET), and CRISPR/Cas9-generated TET2+/- macrophages in vitro. RESULTS: Clonal haematopoiesis of indeterminate potential was associated with increased 3-year mortality (hazard ratio 1.39, 95% confidence interval 1.16-1.65, P < .001) in 2389 matched pairs. Mutations in TET2, ASXL1, DNMT3A, JAK2, PPM1D, SF3B1, SRSF2, and U2AF1 individually conferred higher mortality risk. In human plaques, CHIP mutations were found in lesional macrophages. TET2 CHIP carriers showed increased necrotic core size, inflammation, and reduced plaque stability. Multi-omics profiling revealed up-regulation of lipid metabolism and inflammatory pathways. TET2+/- macrophages exhibited increased LDLR expression and lipid uptake, linked to enhanced chromatin accessibility at the LDLR promoter. These findings were confirmed in carotid plaques, which showed increased LDLR and inflammasome-related gene expression in TET2 CHIP carriers. CONCLUSIONS: Clonal haematopoiesis of indeterminate potential is a predictor of mortality in CAD patients. TET2 mutations promote a pro-atherogenic macrophage phenotype via LDLR up-regulation and inflammatory activation, linking epigenetic dysregulation to adverse outcomes in CAD.
引用
- von Scheidt M, Adkar SS, Krefting J, et al. Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. Eur Heart J. 2026. PMID: 40900105. doi:10.1093/eurheartj/ehaf602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。